Company: XOMAP
Filing Date: 2025-09-03
Form Type: SC TO-T/A
Source: 0001193125-25-195061
Chunk: 4

Company: XOMA Royalty Corp
Filing Date: 2025-09-03
Form: SC TO-T/A
Chunk 4
---
 right to receive contingent cash payments equal to a pro rata share of: (i) 100% of the amount by which the Closing Net Cash, as adjusted for any permitted deductions under CVR Agreement made within ninety (90) days following the Closing Date, in excess of the Closing Net Cash as finally determined in accordance with the Purchase Agreement, (ii) (A) 100% of the net proceeds, calculated in accordance with the CVR Agreement, if any, from any sale, transfer, license or other disposition (a “ Disposition”) of CVR Products prior to the Closing and (B) 75% of the net proceeds, calculated in accordance with the CVR Agreement, if any, from any Disposition of CVR Products occurring following the Closing, in each case for the period beginning at the Closing Date and ending on the 10th anniversary of the Closing Date, and (iii) 75% of the net proceeds, calculated in accordance with the CVR Agreement, if any, from LAVA’s collaborations (A) with Pfizer Inc. (formerly Seagen Inc.) to develop, manufacture and commercialize EGFRd2 (PF-8046052)and (B) with Johnson & Johnson (formerly Janssen) for the discovery and development of novel bispecific antibody-based T cell engagers for the treatment of cancer, including JNJ-89853413,in each case for the period beginning at the Closing Date and ending on the 10th anniversary of the Closing Date. As used herein, “ CVR Products” means (i) each of the product or product candidates developed or commercialized by LAVA, its affiliates or their respective (sub)licensees and known as EGFRd2 (PF-8046052)or JNJ-89853413;(ii) each other product or product candidate discovered, developed, or commercialized pursuant to LAVA’s Existing Partnership Agreements; and (iii) any other product, product candidate or other research program being researched or developed by the LAVA as of the Closing, including the product or product candidate known as LAVA-1266.

| IV. | The sixth paragraph on Page 58 of the Offer to Purchase in the Section entitled “—7. Summary of the               
 Merger Agreement and Certain Other Agreements” is hereby amended and restated in its entirety to read as follows: |

In connection with the execution of the Purchase Agreement, Purchaser entered into tender and support agreements (the “ Support Agreements”) with L